Diagnosis and treatment of acquired haemophilia

Haemophilia

Volumn 16, Issue 102, 2010, Pages 102-106

  Baudo, F ^a   Caimi, T ^a   de cataldo, F ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Acquired haemophilia; Factor VIII inhibitor

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANTIBIOTIC AGENT; AZATHIOPRINE; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8C; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DESMOPRESSIN; IMMUNOGLOBULIN; LUPUS ANTICOAGULANT; MELPHALAN; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RITUXIMAB;

ACQUIRED HEMOPHILIA; ARTICLE; AUTOIMMUNE DISEASE; BLEEDING; BOLUS INJECTION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DISEASE CONTROL; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG TOLERABILITY; HEART INFARCTION; HEMOPHILIA; HUMAN; IMMUNOADSORPTION; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LABORATORY DIAGNOSIS; LUNG EMBOLISM; MUCOSA INFLAMMATION; NEUTROPENIA; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; REMISSION; SALVAGE THERAPY; STROKE;

ADULT; AGED; AGED, 80 AND OVER; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; FACTOR VIIA; FACTOR VIII; FEMALE; HEMOPHILIA A; HEMORRHAGE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; RECOMBINANT PROTEINS;

EID: 77953284386     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02232.x     Document Type: Article

References (27)

1. Collins PW, Hirsch S, Baglin TP. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood 2007, 109:1870-7.
2. Baudo F, de Cataldo F. Acquired haemophilia in the elderly. Blood Disorders in the Elderly 2007, 389-407. Balducci L, Ershler Wde Gaetano G. In, eds, Cambridge, Cambridge University Press
3. Baudo F, Mostarda G, de Cataldo F. Acquired factor VIII and factor IX inhibitors: survey of the Italian Haemophilia Centers (AICE). Haematologica 2003, 88(Suppl. 12):93-9.
4. Sumner MJ, Geldziler BD, Pedersen M, Seremetis S. Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal. Haemophilia 2007, 13:451-61.
5. Croom KP, McCormack P. Recombinant factor Viia (Eptacog alfa). A review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders. Biodrugs 2008, 22:121-36.
6. Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicenter study. Thromb Haemost 1997, 78:1463-7.
7. Baudo F, de Cataldo F, Gaidano G. Treatment of acquired factor VIII inhibitor with recombinant activated factor VIIa: data from the Italian registry of acquired hemophilia. Haematologica 2004, 89:759-61.
8. Sallah S. Treatment of acquired haemophilia with factor eight inhibitor bypassing activity. Haemophilia 2004, 10:169-73.
9. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004, 104:3858-64.
10. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006, 295:293-8.
11. Aledort LM. Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues. Haemophilia 2008, 14:39-43.
12. Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006, 133:591-605.
13. Guillet B, Pinganaud C, Proulle V, Dreyfus M, Lambert T. Myocardial infarction occurring in a case of acquired haemophilia during the treatment course with recombinant activated factor VII. Thromb Haemost 2002, 88:698-9.
14. Hilgartner MW, Knatterud G. The use of factor-eight-inhibitor-by-passing-activity (FEIBA Immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 1983, 61:36.
15. Kasper CK. Human factor VIII for bleeding in patients with inhibitors. Vox Sang 1999, 77(Suppl. 1):47-8.
16. Muhm M, Grois N, Kier P. 1-Deamino-8-D-arginine vasopressin in the treatment of non-haemophilic patients with acquired factor VIII inhibitor. Haemostasis 1990, 20:15-20.
17. Schwartz RS, Gabriel DA, Aledort LM, Green D, Kessler CM. A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin. Blood 1995, 86:797-804.
18. Nemes L, Pitlik E. New protocol for immune tolerance induction in acquired hemophilia. Haematologica 2000, 85(10 Suppl.):64-8.
19. Huth-Kühne A, Lages P, Hampel H, Zimmermann R. Management of severe hemorrhage and inhibitor elimination in acquired hemophilia: the modified Heidelberg-Malmö protocol. Haematologica 2003, 88(S12):86-92.
20. Zeitler H, Ulrich-Merzenich G, Hess L. Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept. Blood 2005, 105:2287-93.
21. Lottenberg R, Kentro TB, Kitchens CS. Acquired haemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med 1987, 147:1077-81.
22. Green D, Lechner K. A Survey of 215 non-haemophilic patients with inhibitors to factor VIII. Thromb Haemost 1981, 45:200-3.
23. Green D. Cytotoxic suppression of acquired factor VIII:C inhibitors. Am J Med 1991, 91(5A):14S-9S.
24. Delgado Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired hemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 2003, 121:21-35.
25. Bussi L, Baudo F, de Cataldo F. Factor VIII concentrate and cyclophosphamide in patients with factor VIII inhibitors. Blood 1974, 44:767.
26. Green D, Rademaker AW, Briet E. A prospective randomized trial of prednisolone and cyclophosphamide in the treatment of patients with factor VIII antibodies. Thromb Haemost 1993, 70:753-7.
27. Sperr WF, Lechner K, Pabinger I. Rituximab for the treatment of acquired antibodies to factor VIII. Haemophilia 2007, 92:66-71.